Jefferies top pharma stocks: Jefferies has a Buy rating ... levels of triglycerides in adults with certain indications. Also, Lupin and Zydus will continue to gain market share in Mirabegron.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Hookipa Pharma (HOOK – Research Report) on February 28 and set a price target of $2.00. The company’s shares closed yesterday at ...

The proposed 25% tariff on Indian pharmaceutical exports to the US has raised concerns about its impact on drug affordability and supply chains. Ramesh Swaminathan, Executive Director, Global CFO, and ...

Mumbai: Global pharma major Lupin Limited has announced its inclusion in prestigious S&P Global Sustainability Yearbook 2025, for the second consecutive year. Lupin has been included in the Top 10% ...

Lupin Ltd gets USFDA nod for generic psoriasis treatment solution Pharmaceutical major Lupin Ltd gets USFDA nod for a generic psoriasis treatment solution. It is the first and only generic ...

What’s the base and worst case scenarios in the event of the tariff hike on pharmaceuticals by the US? (Image Credits: Pixabay) While US President Donald Trump announced the likely imposition of ...

16:00 EST Vincerx Pharma (VINC) Inc trading halted, news pending See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and streamline your search for investmen ...

HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased ...

In light of uncertainties surrounding US tariffs on pharmaceuticals, Kotak Institutional Equities noted in a recent report that the most likely scenario (for both companies and investors ...

Kotak Institutional Equities suggests that high US tariffs on pharmaceuticals are unlikely. They maintain an optimistic outlook on the sector, favouring companies like Sun Pharmaceuticals and Cipla, ...